Measuring AMH for the Prediction of Response to Ovarian Stimulation
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 16-009186
Sponsor Protocol Number: AMH-02-16
About this study
Validate and evaluate the diagnostic performance of AMH for predictin poor ovarian response at the pre-defined cutoff of 0.93 ng/ml in both serum and lithium heparin plasma.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria
- Written informed consent obtained
- ≥21 and <46 years of age
- Planning to undergo ovarian stimulation as part of an IVF protocol
- Regular menstrual cycle
- Both ovaries present
- Able to provide blood sample on Day 2 to 4 of the spontaneous menstrual cycle prior to starting ovarian stimulation
Exclusion Criteria
- Having undergone ≥3 prior cycles of ovarian stimulation for IVF or IVF/ICSI
- Patients undergoingovarian stimulation for egg donation
- Patients undergoing natural cycle IVF (i.e., an IVF cycle without the use of any ovarian stimulation medications)
- Evidence of polycystic ovary syndrome
- Surgically confirmed ovarian endometrioma
- Any ovarian surgery within one year prior to enrollment and study blood draw
- Ovarian cysts ≥20mm
- Exposure to cytotoxic drugs or pelvic radiation therapy for the treatment of cancer
- Hormonal contraceptive use within the two months prior to enrollment and study blood draw
- Currently pregnant
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Charles Coddington, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available